Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Xynomic Presents Positive Long-Term Data on Lead Oncology Candidate

publication date: May 22, 2019

Xynomic Pharma, a Raleigh-Shanghai oncology company, presented positive data from exceptional responders in a long-term follow-up of its lead drug abexinostat (ABX) plus pazopanib. Xynomic says data from the Phase Ib trial show that (1) durable responses with ABX + PAZ are achievable, even in patients with PAZ- and VEGF-refractory RCC and other solid tumor malignancies, and (2) host factors including HDAC expression and acetylation status may identify the patients most likely to benefit from the combination therapy. More details....

Stock symbol: (NSDQ: XYN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.